Get the Stockscreener App
7.55
0.80%
0.06
Fennec Pharmaceuticals Inc stock is traded at $7.55, with a volume of 463.81K.
It is up +0.80% in the last 24 hours and down -2.96% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$7.49
Open:
$7.59
24h Volume:
463.81K
Relative Volume:
3.84
Market Cap:
$257.86M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-12.38
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
+0.00%
1M Performance:
-2.96%
6M Performance:
-9.25%
1Y Performance:
+23.57%
1-Day Range:
$7.45
$7.63
1-Week Range:
$7.35
$7.74
52-Week Range:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
7.55 | 255.81M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
Fennec Pharmaceuticals Announces Private Offering to Bolster Financial Position - MSN
(FRX) Risk-Controlled Trading Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Pfizer (PFE) - The Globe and Mail
How To Trade (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Tumors - marketscreener.com
Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors - marketscreener.com
Fennec Pharma announces City of Hope PEDMARK trial in metastatic testicular tumors | FENC Stock News - Stock Titan
(FRX) Trading Performance and Risk Management (FRX:CA) - news.stocktradersdaily.com
Retail Surge: Will Fennec Pharmaceuticals Inc RV41 stock hit Wall Street targetsMarket Volume Report & Real-Time Sentiment Analysis - BỘ NỘI VỤ
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 - Investing.com
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Director Sells 10,000 Shares - TradingView
Dir Raykov Sells 10,000 ($75.4K) Of Fennec Pharmaceuticals Inc [FENC] - TradingView
Dir Raykov Files To Sell 10,000 Of Fennec Pharmaceuticals Inc [FENC] - TradingView
What hedge fund moves indicate for Fennec Pharmaceuticals Inc. (RV41) stockQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - Newser
Will Fennec Pharmaceuticals Inc. (RV41) stock hit Wall Street targetsTake Profit & Fast Entry High Yield Tips - Newser
Can Fennec Pharmaceuticals Inc. (RV41) stock withstand sector downturns2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
How analysts revise price targets for Fennec Pharmaceuticals Inc. (RV41) stockJuly 2025 Breakouts & Safe Entry Point Identification - Newser
(FENC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Fennec Pharmaceuticals Inc. (RV41) stock benefit from Fed rate cutsDay Trade & Smart Allocation Stock Reports - Newser
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan - MSN
Why Fennec Pharmaceuticals Inc. stock is popular among millennialsMarket Weekly Review & Daily Volume Surge Signals - Newser
(FRX) Technical Pivots with Risk Controls (FRX:CA) - news.stocktradersdaily.com
Is Fennec Pharmaceuticals Inc. stock resilient to inflationInflation Watch & Fast Entry Momentum Alerts - Newser
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Can Fennec Pharmaceuticals Inc. stock attract ESG capital inflows2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Fennec Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Stocks in play: Fennec Pharmaceuticals Inc. - The Globe and Mail
Fennec Pharmaceuticals Inc Announces Positive Results from PEDMARK® Trial in Japan - TradingView
Wedbush on Fennec Pharmaceuticals Latest Japan Trial Results - marketscreener.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Benzinga
Fennec Pharmaceuticals announces positive topline results - marketscreener.com
Fennec Pharmaceuticals Inc. Announces Positive Topline Results from Investigator-Initiated Clinical Study of Pedmark®? in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Reports Positive Top-line Results From Japan Trial - marketscreener.com
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint - marketscreener.com
Fennec’s pediatric hearing protection drug shows positive results in Japan By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Brief: Announcing "Positive" Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - The Manila Times
Is Fennec Pharmaceuticals Inc. (RV41) stock a buy before new product rolloutQuarterly Trade Report & Daily Stock Trend Reports - Newser
(FRX) Long Term Investment Analysis (FRX:CA) - news.stocktradersdaily.com
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33 - Defense World
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
Loss-Making Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Expected To Breakeven In The Medium-Term - Yahoo Finance
Trend Tracker for (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals highlights cisplatin ototoxicity risks - Traders Union
(FENC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):